Wanbury share news, announcements and annual reports
NSE: WANBURYBSE: 524212Pharmaceuticals & BiotechnologySmall Cap
Wanbury Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1992 on BSE, Jan 2007 on NSE
Last close ₹181.93up ₹7.77 (4.46%)BSE ₹180.55
Share price at the NSE close on 29 Oct 2026. Previous close ₹174.16.
29 Oct: open ₹174.92, high ₹185.01, low ₹172.63
52-week range of traded prices to 28 Oct 2026
₹161.50Low, 27 Jan 2026₹358.85High, 15 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹609 Cr1,555th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 10.90
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.22
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 54.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 23.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.49
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,72,769
Wanbury disputes and clarifications
16 filed, newest first.
Jul 2026
17 Jul · Legal
The exchange asked on 16 Jul 2026
Mar 2026
Dec 2025
10 Dec · Legal
Exchange has sought clarification from Wanbury Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1.Consolidated Financial Results not submitted -1. Consolidated Financial Results not submitted The response of the Company is awaited.
Dec 2024
11 Dec · Legal
Exchange has sought clarification from Wanbury Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Oct 2024
Sep 2024
24 Sep · Legal
Exchange has sought clarification from Wanbury Limited with respect to announcement dated 12-Sep-2024, regarding new products launch, its commercialization and pipeline. On basis of above the Company is required to provide following:1. name of the product; 2. date of launch; 3. category of the product; 4. whether caters to domestic/ international market; 5. name of the countries in which the product is launched (in case of international). The response of the Company is awaited.4 Sep · Legal
Exchange has sought clarification from Wanbury Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Feb 2022
18 Feb · Legal
Exchange has sought clarification from Wanbury Limited with respect to announcement dated 17-Feb-2022, regarding appointment of Ms. Anupama Vaidya as an Independent Director of the Company. On basis of above the Company is required to provide confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018. The response of the Company is awaited.
Jun 2017
1 Jun · Legal
Exchange has sought clarification from Wanbury Limited with respect to announcement dated 01-Jun-2017, regarding "Outcome of Board Meeting held on May 30, 2017."On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment;2. Brief profile (in case of appointment);3. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.
Nov 2016
Oct 2016
27 Oct · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned Wanbury Pharma Gets Show cause notice from Thane FDA. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.